N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: A randomized, double-blind, placebo-controlled clinical trial of efficacy and safety

Clinical Neuropharmacology

Volumn 38, Issue 1, 2015, Pages 11-17

  Nikoo, Mohammadali ^a   Radnia, Hanieh ^a   Farokhnia, Mehdi ^a   Mohammadi, Mohammad Reza ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autistic disorder; glutamate; irritability; N acetylcysteine; oxidative stress

Indexed keywords

ACETYLCYSTEINE; PHENOBARBITAL; PLACEBO; RISPERIDONE; VALPROIC ACID; VIGABATRIN;

ABDOMINAL PAIN; ADJUVANT THERAPY; ARTICLE; AUTISM; BEHAVIOR DISORDER; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPILEPSY; FEMALE; HUMAN; HYPERACTIVITY; IRRITABILITY; LETHARGY; MALE; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

EID: 84964306146     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000063     Document Type: Article

References (49)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
2. Mohammadi MR, Akhondzadeh S. Autism spectrum disorders: etiology and pharmacotherapy. Curr Drug Therapy 2007;2(2):97-103.
3. Baio J. Prevalence of autism spectrum disorders-Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012;61:1-19.
4. Leskovec TJ, Rowles BM, Findling RL. Pharmacological treatment options for autism spectrum disorders in children and adolescents. Harv Rev Psychiatry 2008;16(2):97-112.
5. McPheeters ML, Warren Z, Sathe N, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011; 127:e1312-e1321.
6. Nazeer A. Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatr Clin North Am 2011;58(1):85-97.
7. Pardo CA, Eberhart CG. The neurobiology of autism. Brain Pathol 2007; 17(4):434-447.
8. Ratajczak HV. Theoretical aspects of autism: causes-A review. J Immunotoxicol 2011;8(1):68-79.
9. Rubenstein J, Merzenich M. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav 2003;2(5): 255-267.
10. BelmonteMK, Cook E, AndersonGM, et al. Autismas a disorder of neural information processing: directions for research and targets for therapy. Mol Psychiatry 2004;9:646-663.
11. Ghanizadeh A, Akhondzadeh S, Hormozi M, et al. Glutathione-related factors and oxidative stress in autism, a review. Curr Med Chem 2012;19: 4000-4005.
12. Purcell A, Jeon O, Zimmerman A, et al. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 2001; 57:1618-1628.
13. Fatemi SH, Halt AR, Stary JM, et al. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2012;52:805-810.
14. Shinohe A, Hashimoto K, Nakamura K, et al. Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1472-1477.
15. Tirouvanziam R, Obukhanych TV, Laval J, et al. Distinct plasma profile of polar neutral amino acids, leucine, and glutamate in children with autism spectrum disorders. J Autism Dev Disord 2012;42:827-836.
16. Moreno-Fuenmayor H, Borjas L, Arrieta A, et al. Plasma excitatory amino acids in autism. Invest Clin 1996;37:113-128.
17. Aldred S, Moore KM, Fitzgerald M, et al. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 2003; 33:93-97.
18. Niederhofer H. Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. J Clin Psychopharmacol 2007; 27(3):317-318.
19. Harrison C. Neurodevelopmental disorders: glutamate blockers show benefit in models of autism spectrum disorders. Nat Rev Drug Discov 2012;11(6):440-441.
20. Rezaei V, Mohammadi MR, Ghanizadeh A, et al. Double-blind, placebo-controlled trial of risperidone plustopiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34(7):1269-1272.
21. Ghaleiha A, Asadabadi M, Mohammadi MR, et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2013;16(4):783-789.
22. Ghaleiha A, Mohammadi E, Mohammadi MR, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs 2013;15:505-514.
23. Mohammadi MR, Yadegari N, Hassanzadeh E, et al. Double-blind, placebo-controlled trial of risperidone plus amantadine in children with autism: a 10-week randomized study. Clin Neuropharmacol 2013;36: 179-184.
24. Ming X, Stein T, Brimacombe M, et al. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot Essent Fatty Acids 2005;73:379-384.
25. Damodaran LPM, Arumugam G. Urinary oxidative stress markers in children with autism. Redox Rep 2011;16(5):216-222.
26. Essa MM, Guillemin GJ, Waly MI, et al. Increased markers of oxidative stress in autistic children of the Sultanate of Oman. Biol Trace Elem Res 2012;147:25-27.
27. James SJ, Rose S, Melnyk S, et al. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 2009;23:2374-2383.
28. Al-Yafee Y, Al-Ayadhi L, Haq S, et al. Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia. BMC Neurol 2011;11:139.
29. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res 2012;37(8):1681-1689.
30. Bowers K, Li Q, Bressler J, et al. Glutathione pathway gene variation and risk of autism spectrum disorders. J Neurodev Disord 2012;3:132-143.
31. James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet 2006;141:947-956.
32. Yorbik O, Sayal A, Akay C, et al. Investigation of antioxidant enzymes in children with autistic disorder. Prostaglandins Leukot Essent Fatty Acids 2002;67:341-343.
33. Meguid NA, Dardir AA, Abdel-Raouf ER, et al. Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res 2011;143:58-65.
34. Banji D, Banji OJ, Abbagoni S, et al. Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals. Brain Res 2011;1410:141-151.
35. Aruoma OI, Halliwell B, Hoey BM, et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6:593-597.
36. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011;36(2):78-86.
37. Berk M, Malhi GS, Gray LJ, et al. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34(3):167-177.
38. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71(11):956-961.
39. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry 2013;13:196.
40. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24(5):659-685.
41. AmanMG, Singh NN, Stewart AW, et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-491.
42. Akhondzadeh S, Fallah J, Mohammadi MR, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:32-36.
43. Ghaleiha A, Ghyasvand M, Mohammadi MR, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled trial. J Psychopharmacol 2013;28(7):677-685.
44. Asadabadi M, Mohammadi MR, Ghanizadeh A, et al. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2013;225:51-59.
45. Meiri G, BichovskyY, Belmaker R.Omega 3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol 2009;19(4):449-451.
46. Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 2011;41(5):545-554.
47. DolskeMC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993;17(5):765-774.
48. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003;384(4):505-516.
49. Berk M, Malhi GS, Gray LJ, et al. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002;22(20): 9134-9141.